Literature DB >> 21938461

Solitary fibrous tumor of the central nervous system: a clinicopathologic study of 24 cases.

Hong Chen1, Xian-Wei Zeng, Jin-Song Wu, Ya-Fang Dou, Yin Wang, Ping Zhong, Rong Xu, Cheng-Chuan Jiang, Xiao-Qiang Wang.   

Abstract

OBJECTIVE: Solitary fibrous tumor is a rare, spindle-cell benign mesenchymal neoplasm and has a high recurrence rate. In this study, we reviewed our experience in the diagnosis and treatment of 24 patients with central nervous system solitary fibrous tumors.
METHODS: Clinical data were retrieved from the medical records. Prognosis was assessed by clinic service and telephone interview. The specimens were stained with hematoxylin and eosin. Immunohistochemistry for CD34, CD99, EMA, HMB-45, Bcl-2, vimentin, GFAP, S-100, MBP, CK and MIB-1 was performed in all cases. Distributions of time to progression and recurrence were estimated using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: The 24 patients included 13 men and 11 women with a median age of 49.0 years. The most frequent initial symptoms were headache, dizziness, unstable walk and hearing loss. The most common location was cerebellar pontine angle (n = 6). Surgery reached gross total removal for 18 patients but subtotal removal for six patients on initial operation. Histopathologic examination showed spindle to oval cells were disposed in wavy fascicles between prominent, eosinophilic bands of collagen. Dense bands of collagen appeared in cross section as minute nodules that separated individual tumor cells. Cellular areas with a partial hemangiopericytoma pattern were noted in six cases. Atypical presentations were shown on initial operation in three cases. CD34, CD99 and vimentin were 100% positive; but EMA, CK, MBP, HBM-45 and GRAP were 100% negative. The positive in Bcl-2, RF and S-100 was 89%, 85% and 26%, respectively. Follow-up information was available for 23 patients. The median follow-up period was 36.0 months. Nine patients recurred and one patient died from the progression. Incomplete surgical resection was significantly associated with recurrence (p = 0.010). MIB-1 labeling index in recurrence was higher than in no recurrence (6.0% versus 3.4%, p = 0.029). All treated with subtotal removal only had subsequent tumor recurrence or progression; however, the two patients who were administered adjuvant radiosurgery after subtotal removal did not recur or progress. Adjuvant radiosurgery seemed to improve the prognosis (p = 0.028).
CONCLUSIONS: Solitary fibrous tumor is a rare mesenchymal tumor with a propensity to recur. The most affected area is the cerebellopontine angle. Immunohistochemistry should be used to differentiate solitary fibrous tumor from other tumors. The extent of resection, MIB-1 labeling index and some anaplastic features might be predictive for recurrence. Postoperative radiosurgery might be an option in incompletely resected solitary fibrous tumor. Regular and long-term follow-up remains mandatory to monitor recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938461     DOI: 10.1007/s00701-011-1160-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  21 in total

1.  Predictive value of PWI for blood supply and T1-spin echo MRI for consistency of pituitary adenoma.

Authors:  Zengyi Ma; Wenqiang He; Yao Zhao; Jie Yuan; Qilin Zhang; Yue Wu; Hong Chen; Zhenwei Yao; Shiqi Li; Yongfei Wang
Journal:  Neuroradiology       Date:  2015-09-16       Impact factor: 2.804

2.  Surgical management of spinal solitary fibrous tumor/hemangiopericytoma: a case series of 20 patients.

Authors:  Qi Jia; Zhenhua Zhou; Dan Zhang; Jian Yang; Chao Liu; Ting Wang; Zhipeng Wu; Cheng Yang; Haifeng Wei; Jian Zhao; Tielong Liu; Wang Zhou; Xinghai Yang; Jianru Xiao
Journal:  Eur Spine J       Date:  2017-11-10       Impact factor: 3.134

Review 3.  Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review.

Authors:  Bita Geramizadeh; Mahsa Marzban; Andrew Churg
Journal:  Iran J Pathol       Date:  2016

4.  Meningeal haemangiopericytoma and solitary fibrous tumour: a retrospective bi centre study for outcome and prognostic factor assessment.

Authors:  Charles Champeaux; Akbar Ali Khan; Elena Wilson; Lewis Thorne; Laurence Dunn
Journal:  J Neurooncol       Date:  2017-07-10       Impact factor: 4.130

5.  Magnetic resonance features of meningeal solitary fibrous tumors.

Authors:  Xi Li; Lilian Tan; Xiaoming Ouyang; Jindai Jiang; Sumeng Huang; Yong Huang; Shuxin Li; Deji Chen
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

Review 6.  Treatment of orbital solitary fibrous tumour with gamma knife radiosurgery and systematic review of literature.

Authors:  Athreya Tata; Or Cohen-Inbar; Jason P Sheehan
Journal:  BMJ Case Rep       Date:  2016-10-07

7.  Extrathoracic location and "borderline" histology are associated with recurrence of solitary fibrous tumors after surgical resection.

Authors:  Breelyn A Wilky; Elizabeth A Montgomery; Angela A Guzzetta; Nita Ahuja; Christian F Meyer
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

8.  Analyses of prognosis-related factors of intracranial solitary fibrous tumors and hemangiopericytomas help understand the relationship between the two sorts of tumors.

Authors:  Lingcheng Zeng; Yan Wang; Yu Wang; Lin Han; Hongquan Niu; Mengxian Zhang; Changshu Ke; Jian Chen; Ting Lei
Journal:  J Neurooncol       Date:  2016-09-26       Impact factor: 4.130

9.  Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; J Chad Brenner; Jennifer N Stall; Javed Siddiqui; Dafydd G Thomas; David R Lucas; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Am J Clin Pathol       Date:  2013-06       Impact factor: 2.493

10.  Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis.

Authors:  Yang Yu; Yu Hu; Liang Lv; Cheng Chen; Senlin Yin; Shu Jiang; Peizhi Zhou
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.